Literature DB >> 8012974

Human monoclonal antibody identified an immunoreactive tetrapeptide sequence (Lys-Tyr-Gln-Ile) in M(r) 43,000 protein of human melanoma.

T Oka1, Y Kikumoto, K Itakura, D L Morton, R F Irie.   

Abstract

The human monoclonal antibody (HuMAb) L92 reacts to an M(r) 43,000 protein associated with human melanoma. To identify the gene encoding its antigenic epitope, a complementary DNA expression library constructed from the human melanoma cell line UCLASO M14 was screened with HuMAb L92. DNA sequence analysis of the isolated clone revealed that the immunoreactive peptide was composed of 10 amino acids (QDLT-MKYQIF). The peptide was expressed in Escherichia coli with beta-galactosidase as a fused protein. There is no homology between the cloned sequence and other reported DNA sequences. Western blot analysis showed that the fused protein had specific binding to HuMAb L92. An antigen-encoding peptide with 10 amino acids was synthesized and tested for its immunoreactivity in vitro. HuMAb L92 reacted specifically to the 10-amino acid peptide in both an antibody-binding inhibition to the M(r) 43,000 protein and a solid-phase enzyme-linked immunosorbent assay. Using several truncated fusion proteins, we found the minimum number of amino acids required for the antibody binding to be 4 (KYQI). These results suggest that the identified peptide sequence encodes the antigenic epitope of the M(r) 43,000 protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8012974

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine.

Authors:  T Takahashi; A Conforti; Y Kikumoto; D S Hoon; D L Morton; R F Irie
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

2.  A human natural antibody to adenocarcinoma that inhibits tumour cell migration.

Authors:  K Koda; N Nakajima; N Saito; J Yasutomi; M E McKnight; M C Glassy
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.